Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Interdisciplinary Excellence Research Program on Healthy Aging (PIEI-ES), Universidad de Talca, 3460000 Talca, Chile.
Mol Med Rep. 2013 Dec;8(6):1611-6. doi: 10.3892/mmr.2013.1714. Epub 2013 Oct 7.
Metabolic syndrome (MS) includes the presence of arterial hypertension, insulin resistance, dyslipidemia, cardiovascular disease (CVD) and abdominal obesity, which is associated with a chronic inflammatory response, characterized by abnormal adipokine production, and the activation of certain pro-inflammatory signaling pathways. Furthermore, the changes presented by the adipose tissue in MS favors the secretion of several molecular mediators capable of activating or suppressing a number of transcription factors, such as the peroxisome proliferator-activated receptors (PPARs), whose main functions include storage regulation and fatty acid catabolization. When they are activated by their ligands (synthetic or endogenous), they control several genes involved in intermediate metabolism, which make them, together with the PPAR gamma coactivator-1-α (PGC-1) and the silent information regulator T1 (SIRT1), good targets for treating metabolic diseases and their cardiovascular complications.
代谢综合征(MS)包括动脉高血压、胰岛素抵抗、血脂异常、心血管疾病(CVD)和腹部肥胖,这些都与慢性炎症反应有关,其特征是脂联素产生异常和某些促炎信号通路的激活。此外,MS 中脂肪组织的变化有利于多种分子介质的分泌,这些分子介质能够激活或抑制许多转录因子,如过氧化物酶体增殖物激活受体(PPARs),其主要功能包括储存调节和脂肪酸分解代谢。当它们被配体(合成的或内源性的)激活时,它们控制着参与中间代谢的几个基因,这使它们与 PPARγ共激活因子-1-α(PGC-1)和沉默信息调节因子 T1(SIRT1)一起成为治疗代谢性疾病及其心血管并发症的良好靶点。